MRK Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$135.19median target· current $130.21 (+3.8%)29 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
17 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio36.68Forward 48.31
EPS (TTM)$3.55-19.3% YoY
Profit margin13.6%HEALTHCARE
Market cap$307.25BMega cap
Valuation
- Forward P/E
- 48.31
- PEG ratio
- 12.06
- P/B
- 7.01
- P/S (TTM)
- 4.93
- EV/EBITDA
- 18.81
Profitability & growth
- ROE (TTM)
- 18.9%
- Operating margin
- 38.6%
- Revenue growth YoY
- 4.9%
- Dividend yield
- 2.5%
- Beta
- 0.20
Last earnings
Apr 30, 2026 · Estimate $-1.47 · Reported $-1.28
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Merck & Company Inc
Company profileMerck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 126 EAST LINCOLN AVENUE, RAHWAY, NJ
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$307.25B
Shares outstanding$2.47B
52W high$135.05
52W low$75.81
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent